Articles tagged with Hiv Treatments
Researchers found that naltrexone increased the antiviral activity of AZT and indinavir when added to cell cultures containing these drugs. Naltrexone targets infected cells rather than the virus itself, a novel approach to HIV treatment.
A new study published in The Lancet suggests that abacavir-containing regimens are more effective than zidovudine/lamivudine in children with HIV-1 who have not previously been treated. This finding could provide a good NRTI backbone for use with protease inhibitors and non-nucleoside reverse-transcriptase inhibitors.
The SMART trial aims to find a balance between aggressive HIV treatment and minimizing adverse side effects. The study will compare two distinct treatment approaches over an average of seven years, providing valuable insights into the optimal use of antiviral therapy.
A new HIV treatment potential has been discovered through protein discovery by Rutgers cell biologist, Dr. Firestein. The identified protein, HP68, plays a crucial role in the assembly of HIV capsids, and disrupting its interaction with Gag proteins may stop HIV production.
According to Roger J. Pomerantz, M.D., physicians should treat HIV-infected individuals when their CD4 lymphocyte count is below 350 or their HIV RNA level exceeds 50,000, rather than immediately upon diagnosis.
The North-Central California Center for AIDS Research aims to address HIV infection patterns, develop prevention strategies and improve treatment outcomes. The center will foster collaboration between researchers and clinicians to advance knowledge of HIV and its impact on rural communities.
A recent study found that men who believe in the effectiveness of highly active anti-retroviral therapy (HAART) in preventing HIV transmission are more likely to engage in unprotected sex. The study suggests that behavioral interventions targeting these men are needed to promote safe sex practices.
A Yale study found that HIV patients who trust their physicians are 20% more likely to adhere to their treatment regimens. Lack of social support and mistrust in peers also hinder adherence to ART.
A recent study published in The Lancet found that nearly half of people receiving antiretroviral treatment for HIV-1 developed clinical adverse effects, while 27% experienced laboratory adverse effects. The authors emphasize the need for postmarketing surveillance to improve tolerability of anti-HIV-1 treatment.
A study by Johns Hopkins Bloomberg School of Public Health found that nearly one third of eligible injection drug users never received antiretroviral treatment. Methadone addiction treatment, health insurance, and regular access to care were associated with increased HAART use among men.
Researchers are enrolling patients in a clinical trial to investigate the safety and tolerability of early antiretroviral therapy for recently infected HIV patients. The study aims to determine whether early intervention can reduce disease progression, viral mutations, and immune system damage.
A study by Duke University researchers found that HIV patients value high levels of control over medical record access, leading them to choose distant clinics or withhold information. The results highlight the need for providers to prioritize patient confidentiality and provide training on record-keeping and sharing.
Researchers propose integrating highly-active antiretroviral therapy (HAART) into existing tuberculosis-control infrastructure in less-developed countries. Directly-observed therapy has shown effectiveness in resource-poor settings with sustained commitment to uninterrupted care that is free to the patient.
A shorter course of AZT therapy can reduce HIV transmission from mothers to children, now available at a lower cost. The study found that treatment regimens starting at 28 weeks pregnant and given to the infant for six weeks resulted in a transmission rate similar to standard long/long treatment.
A pilot study suggests metformin, a type 2 diabetes drug, may help treat HIV lipodystrophy by reducing insulin levels and improving metabolic changes. The treatment was well-tolerated with no serious side effects reported, but further studies are needed to confirm its effectiveness.
A recent San Francisco study found that antiretroviral treatment continues to significantly improve AIDS patient survival rates, with a 60% reduction in risk of death for those receiving HAART. The study also revealed increased survival benefits over time, particularly among those diagnosed between 1996 and 1997.
Researchers found that women carry lower levels of HIV in their blood than men, especially during early phases of infection, but have the same risk as men of developing AIDS. Current guidelines may lead to more men being eligible for treatment due to lower viral load thresholds.
Despite new treatments extending lives of individuals with HIV, the overall shortfalls in AIDS treatments are becoming apparent. The US data shows a stabilization in AIDS cases and deaths diagnosed each quarter since July 1998, with roughly 4,000 AIDS deaths and 10,000 AIDS cases diagnosed annually.
The updated Guidelines recommend using recently developed tests to determine virus resistance, guiding the selection of new drug regimens. The Panel emphasizes goals of therapy, including suppression of plasma viral load, restoration of immunologic function, and improvement of quality of life.
Physicians at UNC-CH and Duke will receive funding to support care for people living with AIDS across North Carolina and clinical trials promising further medical progress. The renewed national Adult AIDS Clinical Trials Group (AACTG) funding reflects the quality of AIDS research and treatment in North Carolina.
A new study by UCSF researchers found that participants in a therapeutic community-based treatment program made positive changes in drug injection use and high-risk sex. The longer the time spent in treatment, the less likelihood of engaging in high-risk behaviors such as needle sharing.
The new HIVWatch database, developed at UC San Francisco, tracks real-world treatment outcomes for patients with HIV disease. Preliminary data show an increase in CD4 cells among patients at their first clinic meeting, but a stable viral load, suggesting further analysis is needed.
A new model of HIV decline during treatment suggests that antiretroviral therapy drives HIV down to stable levels, varying with drug efficacy. The model proposes that significant numbers of CD4+ T cells become infected with HIV after treatment initiation, leading to a gradual decline in viral load.
A new HIV drug intervention using nevirapine is significantly cheaper and more effective than three similar treatments, preventing 603 infections at a cost of $80,000 per year. The universal nevirapine program is the most cost-effective option, with a treatment cost of $138 to prevent one case of infant HIV.
The American Psychiatric Association is establishing the first comprehensive guidelines for treating persons with HIV infection and AIDS. The new guidelines will focus on access to care, treatment adherence, education, prevention, and direct mental health services.
A survey of nearly 1,000 primary care providers found that those with more experience were more likely to recommend evidence-based treatments for HIV. The study suggests that patients with HIV should have access to experienced physicians who can provide high-quality care.
Community-wide treatment of curable STDs reduced STD rates and improved pregnancy outcomes, but did not reduce new HIV infections in a recent study. The treatment regimen also reduced the prevalence of most targeted STDs, including syphilis and trichomoniasis.
A new study by University of California San Francisco researchers has found that HIV patients who feel part of their community and involved in their own care are more likely to take their medication and follow medical advice. In contrast, those feeling detached or depressed are more likely to disregard treatment.
A new study by researchers at UCSF AIDS Research Institute found that a short-course of antiviral drug therapy and high prevalence of HIV-positive women of child-bearing age can produce a cost-effective outcome. If drug prices are lowered to 25% of the industrialized world cost, treatment for 100 women could cost around $1,014.
A simplified regimen of twice-weekly isoniazid preventive therapy for six months or rifampicin and pyrazinamide for two months was found to be effective in preventing active tuberculosis in HIV-infected individuals. Higher compliance with treatment was observed among those who received the shorter course of treatment.
Researchers found a significant association between clinic experience and survival of women with AIDS, with 71% of patients in high-experience clinics surviving 21 months after diagnosis. The study suggests that physicians who treat a certain illness more frequently may do it better, especially in HIV management.
Researchers at UC Berkeley and UC San Francisco have developed a diagnostic technique that measures T-cell production rates in patients with AIDS. The study found that potent protease inhibitor treatments can increase T-cell production, suggesting new treatment options for patients.
The study aims to measure how effectively combination drug therapy works during the early stages of HIV infection, with a focus on reducing damage caused by the virus. Researchers hope to determine the optimal duration of treatment for maximum benefit and assess the impact of early treatment on immune system chemicals.
A new UNC-CH study found that an antiretroviral drug reduced HIV transmission in men, suggesting a potential decrease in the probability of transmission. The study showed significant drops in virus levels and undetectable HIV in eight out of 11 subjects.
The study results provided conclusive evidence that antiretroviral therapy can reduce the risk of death in people with intermediate-stage HIV disease. Combination therapies showed promise in slowing disease progression and reducing mortality rates, particularly in patients without prior antiretroviral treatment.